Centessa Pharmaceuticals Plc Stock Performance
| CNTA Stock | USD 15.75 0.09 0.57% |
The firm shows a Beta (market volatility) of -0.0188, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Centessa Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Centessa Pharmaceuticals is likely to outperform the market. At this point, Centessa Pharmaceuticals has a negative expected return of -0.13%. Please make sure to confirm Centessa Pharmaceuticals' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to decide if Centessa Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Centessa Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.02 | Five Day Return (3.98) | Year To Date Return (9.09) | Ten Year Return (26.85) | All Time Return (26.85) |
1 | Disposition of 87496 shares by Saha Saurabh of Centessa Pharmaceuticals at 18.4609 subject to Rule 16b-3 | 12/06/2024 |
2 | Disposition of 5876 shares by Karen Anderson of Centessa Pharmaceuticals at 3.85 subject to Rule 16b-3 | 12/13/2024 |
3 | Disposition of 10624 shares by Karen Anderson of Centessa Pharmaceuticals at 3.85 subject to Rule 16b-3 | 12/17/2024 |
4 | Disposition of 55000 shares by Saha Saurabh of Centessa Pharmaceuticals at 17.4374 subject to Rule 16b-3 | 12/20/2024 |
5 | Disposition of 10000 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 3.85 subject to Rule 16b-3 | 12/26/2024 |
6 | Disposition of 6419 shares by Tia Bush of Centessa Pharmaceuticals at 16.35 subject to Rule 16b-3 | 12/31/2024 |
7 | Insider Trading | 01/06/2025 |
8 | Disposition of 6000 shares by Hussain Iqbal J of Centessa Pharmaceuticals at 15.29 subject to Rule 16b-3 | 01/15/2025 |
9 | Disposition of 87496 shares by Saha Saurabh of Centessa Pharmaceuticals at 5.84 subject to Rule 16b-3 | 01/16/2025 |
10 | Disposition of 1625 shares by Saha Saurabh of Centessa Pharmaceuticals at 16.1937 subject to Rule 16b-3 | 01/21/2025 |
11 | Centessa Pharmaceuticals Stock Price Down 3.4 percent Heres What Happened | 01/24/2025 |
12 | Disposition of 11742 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 16.4733 subject to Rule 16b-3 | 01/27/2025 |
13 | Centessa Pharmaceuticals PLC Announces Participation in Key Investor Conferences | 01/28/2025 |
14 | First Light Asset Management, LLC Acquires Additional Shares in Paragon 28 Inc | 01/30/2025 |
15 | Disposition of 13324 shares by David Chao of Centessa Pharmaceuticals at 16.92 subject to Rule 16b-3 | 01/31/2025 |
16 | Disposition of 11000 shares by Tia Bush of Centessa Pharmaceuticals at 16.8551 subject to Rule 16b-3 | 02/03/2025 |
17 | Centessa Pharmaceuticals plc CTO Sells 185,460.00 in Stock - MarketBeat | 02/05/2025 |
18 | Disposition of 429 shares by Karen Anderson of Centessa Pharmaceuticals at 18.99 subject to Rule 16b-3 | 02/10/2025 |
19 | Disposition of 1388 shares by Hussain Iqbal J of Centessa Pharmaceuticals at 17.0527 subject to Rule 16b-3 | 02/18/2025 |
20 | Disposition of 775 shares by Saha Saurabh of Centessa Pharmaceuticals at 16.5426 subject to Rule 16b-3 | 02/20/2025 |
21 | Disposition of 11494 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 15.2488 subject to Rule 16b-3 | 02/25/2025 |
| Begin Period Cash Flow | 393.6 M |
Centessa |
Centessa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,791 in Centessa Pharmaceuticals PLC on November 28, 2024 and sell it today you would lose (200.00) from holding Centessa Pharmaceuticals PLC or give up 11.17% of portfolio value over 90 days. Centessa Pharmaceuticals PLC is currently does not generate positive expected returns and assumes 3.6645% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Centessa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Centessa Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Centessa Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Centessa Pharmaceuticals PLC, and traders can use it to determine the average amount a Centessa Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0368
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CNTA |
Estimated Market Risk
| 3.66 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Centessa Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Centessa Pharmaceuticals by adding Centessa Pharmaceuticals to a well-diversified portfolio.
Centessa Pharmaceuticals Fundamentals Growth
Centessa Stock prices reflect investors' perceptions of the future prospects and financial health of Centessa Pharmaceuticals, and Centessa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Centessa Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (23.59) % | ||||
| Current Valuation | 1.64 B | ||||
| Shares Outstanding | 131.84 M | ||||
| Price To Book | 4.16 X | ||||
| Price To Sales | 303.01 X | ||||
| Revenue | 6.85 M | ||||
| Gross Profit | 6.85 M | ||||
| EBITDA | (166.07 M) | ||||
| Net Income | (151.09 M) | ||||
| Cash And Equivalents | 484.16 M | ||||
| Cash Per Share | 5.13 X | ||||
| Total Debt | 84.59 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.48 X | ||||
| Book Value Per Share | 3.79 X | ||||
| Cash Flow From Operations | (160.34 M) | ||||
| Earnings Per Share | (1.52) X | ||||
| Market Capitalization | 2.08 B | ||||
| Total Asset | 360.25 M | ||||
| Retained Earnings | (752.95 M) | ||||
| Working Capital | 275.71 M | ||||
About Centessa Pharmaceuticals Performance
By analyzing Centessa Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Centessa Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Centessa Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Centessa Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -75.3 K | -79 K | |
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.74) | (0.77) |
Things to note about Centessa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Centessa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Centessa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Centessa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Centessa Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 6.85 M. Net Loss for the year was (151.09 M) with profit before overhead, payroll, taxes, and interest of 6.85 M. | |
| Centessa Pharmaceuticals PLC currently holds about 484.16 M in cash with (160.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.13. | |
| Centessa Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 11494 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 15.2488 subject to Rule 16b-3 |
- Analyzing Centessa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Centessa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Centessa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Centessa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Centessa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Centessa Pharmaceuticals' stock. These opinions can provide insight into Centessa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Centessa Stock analysis
When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |